Elisidepsin: Antineoplastic agent

Drugs of the Future

Volumn 35, Issue 4, 2010, Pages 287-296

  Coronado, C ^a   Galmarini, C M ^a   Alfaro, V ^a   Yovine, A ^a  

^a PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEPSIPEPTIDE; ELISIDEPSIN; ERLOTINIB; GEMCITABINE; IRVALEC; KAHALALIDE F; PM 02734; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; CELL DEATH; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ESOPHAGUS CANCER; GASTROINTESTINAL CARCINOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NONHUMAN; PRURITUS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TUMOR CELL LINE; TUMOR XENOGRAFT;

EID: 77954596498     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.04.1497635     Document Type: Article

References (20)

1. Tubby, D.G., Francesch Solloso, A., Lopez Macia, A. et al. (PharmaMar SA). Convergent synthesis for kahalalide compounds. EP 1749023, JP 2008506633, US 2007207948, WO 2005103072.
2. Faircloth, G.T., Elices, M., Sasak, H., Aviles Marin, P.M., Cuevas Marchante, M.D.C. (PharmaMar SA). 4-Methylhexanoic kahalalide F compound. CA 2501089, EP 1572726, JP 2006517195, US 2006234920, US 2008119397, WO 2004035613.
3. Albericio Palomera, F., Giralt Lledo, E., Lopez Rodriguez, P. et al. (PharmaMar SA). New antitumoral compounds. EP 1664093, EP 1918296, JP 2007526904, US 2007117743, WO 2005023846.
4. Albericio, F., Giralt, E., Jimenez, J.C., Royo, M., Manzanares, I., Rodrigues, I., Lopez, A. (PharmaMar SA). Kahalalide compounds. WO 2001058934.
5. Faircloth, G., Cuevas, C. Kahalalide F and ES285: Potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 2006, 43: 363-79.
6. Hamann, M.T., Otto, C.S., Scheuer, P.J., Dunbar, D.C. Kahalalides: Bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. (1). J Org Chem 1996, 61(19): 6594-600.
7. Sparidans, R.W., Stokvis, E., Jimeno, J.M., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H. Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anticancer Drugs 2001, 12(7): 575-82.
8. Provencio, M., Sanchez, A., Gasent, J., Gomez, P., Rosell, R. Cancer treatments: Can we find treasures at the bottom of the sea? Clin Lung Cancer 2009, 10(4): 295-300.
9. Molina-Guijarro, J.M., Moneo, V., Martínez-Leal, J.F., Cuevas, C., García-Fernández, L.F., Galmarini, C.M. PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 888.
10. Herrero, A.B., Astudillo, A.M., Balboa, M.A., Cuevas, C., Balsinde, J., Moreno, S. Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 2008, 68(23): 9779-87.
11. Ling, Y.H., Aracil, M., Jimeno, J., Perez-Soler, R., Zou, Y. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 2009, 45(10): 1855-64.
12. Serova, M., Bieche, I., Astorgues-Xerri, L. et al. Characterization of genetic factors associated with sensitivity to Irvalec, a novel marine-derived compound. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 857.
13. Sasak, H., Yin, J., Elices, M., LePage, D., Cuevas Marchante, C., Avilés, P., Faircloth, G. PM02734 cytotoxicity in vitro and pharmacokinetics. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1911.
14. Elices, M., Lepage, D. J., Grant, W. et al. Activity of PM02734 against human breast and prostate tumors. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1107.
15. Serova, M., Astorgues-Xerri, L., Koumaravel, J., Aracil, M., Faivre, S., Raymond, E. Irvalec, a novel marine cyclic peptide, enhances the antiproliferative effects of other anticancer drugs in human cancer cell lines. Proc Am Assoc Cancer Res (AACR) 2009, Abst 4569.
16. Yin, J., Aviles, P., Lee, W. et al. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. Rapid Commun Mass Spectrom 2006, 20(18): 2735-40.
17. Bruce, J.Y., Geary, D., de las Heras, B. et al. Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26: Abst 2513.
18. Evans, T.R., Oaknin, A., Jones, R.J. et al. Phase I dose-escalating study of PM02734 in a 24-hour infusion schedule every 21 days in advanced solid tumors. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 2511.
19. Pardo, B., Paz-Ares, L., Tabernero, J. et al. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res 2008, 14(4): 1116-23.
20. Provencio, M., Izquierdo, A., Viñolas, N., Paz-Ares, L., Feliu, J., Constenla, M.I. Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol [31st Eur Soc Med Oncol Congr (ESMO) (Sept 29-Oct 3, Istanbul) 2006] 2006, 17: Abst 755P.